Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis

Alpha Mannosidosis Clinical Trial

Official title:
A Single Center, Randomized, Open-label, Multiple-dose Study of the Efficacy and Long-term Safety of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) for the Treatment of Patients With Alpha-mannosidosis.

Status Unknown status

Clinical Trial Summary

This is a single-center, open-label, multiple-dose study of the efficacy and long-term safety of Lamazym for the treatment of patients with alpha-mannosidosis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01285700
Study type	Interventional
Source	Zymenex A/S
Contact
Status	Unknown status
Phase	Phase 2
Start date	January 2011
Completion date	November 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01268358` - Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis	Phase 1
Completed	`NCT00498420` - The Natural History of Alpha-Mannosidosis
Terminated	`NCT00668564` - Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism	Phase 2
Completed	`NCT01043640` - Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders	Phase 2
Completed	`NCT01891422` - Longitudinal Studies of the Glycoproteinoses